
Evaluation of Tumor Infiltrating Lymphocytes (TILs) in Urothelial Carcinoma

Guidelines for TILs assessment from "International Immuno-Oncology Biomarker Working Group"


Authors: Thomas Gevaert¹ and Yves Allory²

1- KU Leuven and AZ Klina, Belgium. 2-Université Paris-Est, INSERM and APHP, Hôpital Henri-Mondor, France.


- TILs should be evaluated within the borders of the invasive tumor
- The invasive edge is included in the evaluation, but not reported separately
- Immune infiltrates
 outside of the tumor
 borders are not
 included




- TILs should be evaluated within the borders of the invasive tumor
- The invasive edge is included in the evaluation, but not reported separately
- Immune infiltrates outside of the tumor borders are not included




Include TILs evaluation in stroma pertaining to fibrovascular cores of **INVASIVE** papillary structures



Exclude TILs evaluation in stroma pertaining to fibrovascular cores of **NON-INVASIVE** papillary structures




Determine the localization of inflammatory infiltrate



Stromal TILs (sTILs)

Intratumoral TILs (iTILs)

Determine the localization of inflammatory infiltrate




Stromal TILs (sTILs)


Intratumoral TILs (iTILs)

Only mononuclear leukocytes should be scored


- Exclude polymorphonuclear leukocytes from the assessment of TILs
- In this case the frequent eosinophils should be excluded
- Include lymphocytes and plasma cells




Exclude TILs in tumor zones with necrosis



Exclude TILs in areas with coagulation artefacts



Exclude TILs in previous biopsy sites



 Patients with UC often have a history of repetitive TURBT procedures

In this case the areas with giant cell reaction after TURBT should be excluded from assessment of TILs